NICE says final yes to Bayer's Xarelto for blood clots
This article was originally published in Scrip
Executive Summary
In final guidance published today, NICE, the health technology appraisals institute for England and Wales, has recommended Bayer's anticoagulant Xarelto (rivaroxaban) for treating deep vein thrombosis and preventing recurrent DVT and pulmonary embolism in adults diagnosed with DVT. The guidance marks the first time in 20 years that patients will have an alternative to current dual therapy approach.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.